The PKCβ inhibitor, Ruboxistaurin, an LY379196 analogue, is currently in phase I/II evaluation for treatment of heart failure (NCT02769611), however, is listed in this documentation as a PKCα inhibitor. Here, PRKCA is linked to heart failure.